Clinical Trial Detail

NCT ID NCT03846583
Title Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Abemaciclib + Trastuzumab + Tucatinib

Age Groups: adult senior

Additional content available in CKB BOOST